Perioperative outcomes of ongoing antithrombotic therapy during endoscopic surgery for benign prostatic hyperplasia: a systematic review and meta-analysis of observational studies [0.03%]
良性前列腺增生内镜手术中继续使用抗凝血药物的围手术期结局：观察性研究的系统评价和meta分析
Carlo Giulioni,Angelo Cafarelli,Federico Falsetti et al.
Carlo Giulioni et al.
Background: The management of antithrombotic therapy in patients undergoing endoscopic surgery for benign prostatic hyperplasia (BPH) remains challenging due to competing risks of thromboembolism and perioperative bleedin...
The impact of minimally invasive surgical therapy for Benign prostatic hyperplasia on sexual function: a systematic review and meta-analysis [0.03%]
微创手术治疗良性前列腺增生对性功能影响的系统评价和 Meta 分析
Ellen M Cahill,Marcelo Mass Lindenbaum,Alexander Estright et al.
Ellen M Cahill et al.
Introduction: Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) can significantly impair a man's quality of life. While traditional surgical treatments are effective, they often pose ri...
PSMA-PET imaging in prostate cancer patients with high-risk biochemical recurrence: implications from an "EMBARK-Like" cohort [0.03%]
前列腺癌高危生化复发患者的PSMA-PET影像检查：“EMBARK-Like”队列的临床意义
Matteo Droghetti,Valerio Pirelli,Francesco Ceci et al.
Matteo Droghetti et al.
The EMBARK trial demonstrated improved survival with enzalutamide plus androgen deprivation therapy (ADT) in non-metastatic hormone-sensitive prostate cancer patients with high-risk biochemical recurrence (BCR), although staged using conven...
Robot-assisted MRI/US transperineal target prostate biopsy with Biobot Mona Lisa 2.0: first experience in Europe [0.03%]
机器人辅助MRI/超声经会阴靶向前列腺穿刺活检（Biobot Mona Lisa 2.0）：欧洲首次应用体验
Enrico Checcucci,Gabriele Bignante,Gabriele Volpi et al.
Enrico Checcucci et al.
Introduction: The Mona Lisa 2.0 robotic platform integrates MRI/ultrasound fusion, AI-based prostate segmentation, and automated needle trajectory planning to optimize transperineal targeted biopsy (TB) precision. ...
Survival trend in metastatic prostate cancer two decades of real-world data on overall survival from Germany [0.03%]
基于德国二十年真实世界数据的转移性前列腺癌生存趋势研究
Marcus Sondermann,Anton Stehr,Christopher Hirtsiefer et al.
Marcus Sondermann et al.
Background: The management of metastatic prostate cancer (mPCa) has undergone revolutionary changes over the past two decades with the introduction of novel hormonal agents, chemotherapy combinations, PARP inhibitors, and...
Missing the full picture: Pathology, anatomy, and operator effects in HoLEP comparisons [0.03%]
不完整的分析：HoLEP对比研究中的病理、解剖及操作者因素影响
Zuomin Wang,Qinwei Liu,Wangdong Deng
Zuomin Wang
Letter: The Hawthorne effect-behavioral changes from research observation-as confounder and mediator in the ERASE trial [0.03%]
来信：霍桑效应——ERASE试验中的混杂因素和中介因素
Zuomin Wang,Qinwei Liu,Wangdong Deng
Zuomin Wang
Single-port transvesical enucleation of the prostate (STEP) for benign prostatic hyperplasia: a comparative analysis of patients with large (80-150cc) and very large (>150cc) prostate volumes [0.03%]
单端口经膀胱前列腺剜除术（STEP）治疗良性前列腺增生：大体积（80～150毫升）和巨大体积（>150毫升）前列腺的患者比较分析
Salim K Younis,Nicolas A Soputro,Adriana M Pedraza et al.
Salim K Younis et al.
Introduction: Single-Port Transvesical Enucleation of the Prostate (STEP) is a minimally invasive robotic technique for managing benign prostatic hyperplasia (BPH), particularly in prostates ≧ 80 cc. However, its outcome...
Modern day cost analysis demonstrates medical therapy as a highly cost‑effective first‑line treatment for BPH/LUTS [0.03%]
现代的成本分析证明药物治疗是一种高效且经济的BPH/LUTS一线治疗手段
Alexis E Te,Ashwin Ramaswamy,Steven A Kaplan
Alexis E Te
Background/objectives: Generic competition has markedly reduced the cost of medications for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), potentially reshaping the value proposition of first-...
Telesurgery in prostate cancer: a systematic review of clinical applications and future directions [0.03%]
前列腺癌的机器人手术：临床应用及发展方向的系统评价
Boran Aksakal,Nicolas A Soputro,Abdulrahman Al-Bayati et al.
Boran Aksakal et al.
Introduction: Telesurgery represents an emerging frontier in the surgical management of prostate cancer, offering innovative solutions to expand access to specialized care across geographic and institutional barriers. Thi...